Decalcification of Breast Cancer Bone Metastases with EDTA Does Not Affect ER, PR, and HER2 Results by Van Es, S.C. (Suzanne C.) et al.
Decalcification of Breast Cancer Bone Metastases With
EDTA Does Not Affect ER, PR, and HER2 Results
Suzanne C. van Es, MD,* Bert van der Vegt, MD, PhD,† Frederike Bensch, MD, PhD,*
Sophie Gerritse, MD,‡ Erik J. van Helden, MD,‡ Eline Boon, MD,§ Lindsay Angus, MD,∥
Jelle Overbosch, MD,¶ Catharina W. Menke-van der Houven van Oordt, MD, PhD,‡
Henk M. Verheul, MD, PhD,‡ Carla M.L. van Herpen, MD, PhD,§ Agnes Jager, MD, PhD,#
Sjoukje F. Oosting, MD, PhD,* Elisabeth G.E. de Vries, MD, PhD,*
and Carolina P. Schröder, MD, PhD*
Abstract: In metastatic breast cancer (MBC), expression of es-
trogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor-2 (HER2) guides treatment
selection. In case of bone-only metastatic disease, ER, PR, and
HER2 status assessment may be hampered by decalcification.
We aimed to determine the optimal decalcification method, and
to study discordance of receptor expression between paired
primary breast tumors and optimally decalcified bone meta-
stases. First, decalcification was simulated using acetic acid,
hydrochloric/formic acid, and EDTA on 12 primary breast car-
cinomas. ER, PR, and HER2 immunohistochemistry (IHC) and
HER2 in situ hybridization (ISH) were assessed, before and after
the 3 decalcification methods. EDTA was considered the optimal
method, as it did not affect IHC and as ISH failed in only 1/16
cases. Hydrochloric/formic acid altered ER and PR results, and,
with acetic acid and hydrochloric/formic acid, ISH failed in, re-
spectively, 94% and 100%. Second, ER, PR, and HER2 IHC was
performed in paired primary tumors and EDTA-decalcified bone
metastases obtained from patients with first presentation of
MBC. Clinically relevant discordance was defined as changed
receptor status with treatment implications. Paired samples of 77
patients, participating in the IMPACT-MBC trial, were evalu-
able. Hormonal receptor expression change was clinically rele-
vant in 6 patients (7.9%) and HER2 expression change in 1
patient (1.3%). This study shows that EDTA decalcification
minimally affects receptor expression results. The incidence of
clinically relevant discordance between the primary tumor and
bone metastases is low. These findings support that bone biopsies
can reliably be used to assess receptor status.
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In metastatic breast cancer (MBC), discordance ofcharacteristics such as expression of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
growth factor receptor-2 (HER2) between the primary
tumor and metastasis can have therapeutic implications.1
The National Comprehensive Cancer Network guidelines
for breast cancer state that first recurrence of disease
should be biopsied to determine ER, PR, and HER2
status of the metastasis.2 False-negative ER and/or PR
results occur, but there may also be true receptor dis-
cordance between the primary tumor and metastases due
to cause of loss of expression, that is, conversion.2,3 Ap-
proximately 70% of all advanced breast cancer patients
develop bone metastases during the course of their
disease,4 and 51% of patients with a history of breast
cancer suffer a first relapse with bone-only disease.5 Pa-
tients’ compliance with bone biopsy is acceptable, and the
prevalence of complications is low. Antigenicity of the
tumor cells, however, may be affected by decalcification
methods.6,7 Decalcification is needed to enable sectioning
of the specimen. Conflicting results are reported with re-
gard to the reliability of pathologic assessment in decal-
cified tissue. A study that used immunohistochemistry
(IHC) for HER2 and HER2 fluorescent in situ hybrid-
ization (FISH) in 149 breast cancer bone metastases
showed an excellent success rate, with interpretable FISH
analysis in 85% of cases and high concordance between
IHC and FISH.7 In 107 patients with MBC, rather high
discordance rates in ER, PR, and HER2 results between
the primary tumor and bone metastasis were found
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(20.5%, 43.9%, and 6.9%, respectively). This was in line
with the results of previous studies in nonosseous
metastases.1 However, several in vitro experiments
showed a negative effect of decalcification on the im-
munoreactivity of breast cancer biomarkers and HER2
FISH.8–11 One explanation for the contradictive results
could be the various decalcification methods that are used,
with different decalcification agents and decalcification
time spans. Currently, there is no gold standard for de-
calcification. As false-negative results may clearly affect
treatment decision and patient outcome in MBC, it is of
great importance to clarify the reliability of IHC of bone
metastases after decalcification.
The aims of this exploratory study were to, first,
determine the optimal decalcification method by inves-
tigating which decalcification method has the least influ-
ence on ER, PR, and HER2 expression and, second, to
study the discordance rates of ER, PR, and HER2 ex-
pression between paired primary breast tumors and bone
metastases decalcified using the optimal method.
MATERIALS AND METHODS
Aim 1. Assess the Optimal Decalcification
Method
Tissue Selection
Redundant material of 20 different primary breast
cancers was collected, regardless of IHC characteristics.
According to Dutch law and institutional guidelines, no
informed consent was needed. The objection register of the
institutions were consulted; none of the patients had objected
to the use of redundant material for scientific purposes.
Tumor Histology
All tumors were fixed in buffered formalin for 24 to
48 hours, and, of each tumor, 7 blocks were obtained. One
was processed according to standard. The other blocks were
subjected to EDTA (Titriplex III 20%, phosphate-buffered
formalin 4% and sodium hydroxide 2% in distilled water
[pH 7.0 to 7.2]), hydrochloric/formic acid (sodium citrate
0.8%, formic acid 2%, hydrochloric acid 1.5% in distilled
water), or acetic acid (3.5—4% formaldehyde and 10%
acetic acid in distilled water) for 24 or 48 hours.
All samples were embedded in paraffin. From each
block, 3 cores were randomly included in a tissue micro-
array. Three-micrometer sections were cut, and ER (SP1;
Ventana, Illkirch, France), PR (1E2; Ventana), and HER2
(SP3; Ventana) were stained with a Benchmark Ultra
Automated stainer (Ventana) according to the manu-
facturer’s manual. Antibodies were prediluted by the
supplier. FISH (PathVysion HER2 DNA Probe kit, Ab-
bott Molecular, IL) and silver in situ hybridization (ISH)
(INFORMHER2 Dual ISH DNA Probe Cocktail; Ventana)
assays were performed following the manufacturer’s recom-
mendations. All samples were scored by an experienced breast
pathologist who was blinded to the decalcification method
and time. ER, PR, and HER2 were scored according to the
ASCO/CAP guidelines.12,13
Statistical Analysis
Descriptive statistics were used to evaluate the results
of this decalcification experiment. The overall discordance
rate (ODR) and the 95% confidence interval (CI), using the
Wilson score method, were calculated.
Aim 2. Assess the Discordance Rate between
Primary Tumor and Bone Metastasis With the
Optimal Decalcification Method
Tissue Selection
The tumor tissues of patients enroled in the IM-
PACT-MBC trial (NCT01957332) between September
2013 and May 2018, who had undergone a bone meta-
stasis biopsy (n= 96), were selected. Of these, only cases
with bone metastases that were decalcified using the op-
timal decalcification method, as assessed in the above-
mentioned experiment, and of which revised and paired
data were available, were included (n= 77).
The IMPACT-MBC trial includes newly diagnosed
MBC patients, with nonrapidly progressive disease, who
were eligible for first-line systemic treatment. This multi-
center study, conducted at the University Medical Center
Groningen (UMCG), Amsterdam University Medical
Center (UMC), location VU Medical Center (VUmc),
Radboud University Medical Center (Radboud UMC), and
Erasmus Medical Center (Erasmus MC), was approved by
the Medical Ethical Committee of the University Medical
Center Groningen and the Central Committee on Research
Involving Human Subjects. All patients gave written in-
formed consent for central evaluation of the primary tumor,
biopsy of a metastatic lesion, and (central) assessment of the
molecular characteristics of the metastasis. Here, we present
an analysis of the standard pathologic assessments of the
tumor tissue.
Tumor Histology
In all centers, bone biopsies were formalin fixed. In
the UMCG and Radboud UMC, the specimens (n= 75)
were decalcified using EDTA for 24 hours at room tem-
perature, or, if the decalcification process was incomplete,
for 48 hours. In the Erasmus MC, EDTA decalcification
was applied, for ∼7 hours, at 37°C (n= 10). In the Am-
sterdam-UMC location, VUMC sakura TDE30 (without
electrolysis) was used to decalcify the tissue for a duration
of at least 60 minutes and up to a maximum of 90 minutes;
therefore, the tissues of these patients (n= 11) were ex-
cluded. IHC for ER, PR, and HER2, HER2 FISH, and
HER2 SISH was performed according to the protocol
described above. Both primary breast tumors and bone
biopsies were centrally evaluated by a dedicated breast
pathologist at the UMCG.
Statistical Analysis
The ODR and the 95% CI, using the Wilson score
interval, were calculated. McNemar test was used to
compare the prevalence of ER, PR, and HER2 receptor
status between the primary tumor and bone metastases.
The percentage ER and PR expression of paired samples
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of the primary tumor and the bone metastasis were eval-
uated using the Wilcoxon Signed Rank test. P-value <0.05
was considered a statistically significant discordance. In
case of multiple primary breast tumors, the most recent
tumor was used. Clinically relevant discordance was de-
fined as a change of receptor status, with treatment im-
plications.
Data were analyzed using IBM SPSS statistics ver-
sion 23 (SPSS Inc., Chicago, IL).
RESULTS
Aim 1. Optimal Decalcification Method
Of the 20 fresh residual primary breast cancer tis-
sues, 8 did not contain any invasive tumor. After pro-
cessing, 1 of 12 cases was excluded for IHC analyses,
because the standard processed (control) sample lacked
tumor cells. One other sample was excluded for ER and
PR analyses because of the same reason; this case was
available for HER2 analysis. The 10 remaining tumors for
all IHC analyses were ER+PR+HER2− (n= 6), ER+PR
−HER2− (n= 1), ER−PR−HER2+ (n= 1), and ER−PR
−HER2− (n= 2). The extra tumor for the HER2 IHC was
HER2−. For SISH analyses, 1/12 tissues did not contain
tumor cells in the control sample, and, in 3/12, SISH failed
on the control sample, leaving 8 tissues for ISH analysis.
For FISH analyses, in 6/12 tissues, FISH failed on the
control sample. For both IHC and ISH analyses, both
blocks, decalcified for 24 and 48 hours, were studied.
In Table 1, the effects of the 3 decalcification agents
on ER, PR, and HER2 IHC are summarized. No IHC
receptor status result was altered by acetic acid; however,
technical SISH failure occurred in 15/16 cases with
interpretable control ISH, and FISH failed in 12/12
cases. The use of hydrochloric/formic acid resulted in
false-negative ER staining in 3 of 7 ER-positive tumors
(ODR 30%; 95% CI, 11%-60%), which showed 60%, 60%,
and 70% ER staining in the control block. False-negative
PR staining occurred in 2/6 PR-positive tumors (ODR
20%; 95% CI, 6%-51%), which showed 20% and 40% PR
positivity in the control. Decalcification for 48 hours with
hydrochloric/formic acid decreased HER2 IHC from 3+
into 2+ (1/1). Technical SISH and FISH failure was
observed in all cases. EDTA altered no IHC receptor
status result, SISH failed in 1 of 16 cases, and FISH
showed 100% concordance with the control samples.
EDTA was, therefore, considered the most optimal
decalcification method.
Aim 2. Discordance Rate Between Primary
Tumor and Bone Metastasis With Optimal
Decalcification Method
Tumor Characteristics
Figure 1 shows the CONSORT flow diagram,
describing the selection process of the tumor tissue from
the IMPACT-MBC study. All 77 metastatic tissues were
obtained from female patients, with a median tumor
relapse time of 75.8 months (range, 0.6 to 293.5 mo). For
the evaluation of percentage of ER and PR staining in
paired primary tumors and bone metastases, 1 extra case
was excluded, because no exact percentages could be given
for ER and PR staining of the metastasis. The histologic
subtype of the primary tumor was invasive carcinoma of
no special type in 72.7%, lobular carcinoma in 26%, and
carcinoma with apocrine differentiation in 1.3% of cases.
ER Staining
Table 2 shows the ER status of the primary tumors
and metastases. Five of 77 patients had an ER-positive
primary tumor and an ER-negative bone metastasis, and 1
TABLE 1. Comparison of the Effects of Acetic Acid,
Hydrochloric/Formic Acid, and EDTA on IHC and the Clinical























HER2 0, −0.3 (−1 to 0) −1, −0.8 (−2 to 0) 0, −0.3 (−2 to 0)
FIGURE 1. CONSORT diagram reflecting the selection process
of the tumor tissue from the IMPACT breast study. Of the 217
included patients, between September 2013 and May 2018,
96 patients underwent bone biopsy, of which 77 were evalu-
able for this analysis.
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patient had an ER-negative primary tumor and ER-
positive bone metastasis; ODR 7.8% (95% CI, 4%-16%)
(P= 0.219).
The median ER expression was 100% for both the
primary tumors and the bone metastases; the mean ER
expression was 81% for the primary tumors and 73% for
the bone metastases. ER expression of paired primary
tumor and bone metastasis was discordant in 31 of the 76
patients (P= 0.044), with a median change in IHC ex-
pression of −20% (range, −100% to +99%). An increase in
ER expression was seen in 17% of patients (median 20%,
range 5% to 99%). A decline in ER expression was ob-
served in 24% of patients (median 25%, range 20% to
100%). In 59% of cases, the percentage of ER expression
remained the same (Fig. 2).
PR Staining
Table 3 shows the PR status of the primary tumors
and metastases; 15.6% (12/77) of patients had PR-positive
primary tumor and negative bone metastasis biopsy, and
5.2% (4/77) of patients had PR-negative primary tumor,
with positive PR staining of the bone metastasis biopsy;
ODR 20.8% (95% CI, 13%-31%) (P= 0.077).
The median PR expression was 70% for the primary
tumors and 40% for the bone metastases; the mean ex-
pression was, respectively, 57% and 44%. Paired testing of
the percentage PR expression of the primary tumor and the
bone metastasis (n= 76) was discordant in 50 of the 76
patients (P = 0.009), with a median change of IHC ex-
pression of −12.5% (range −100% to +100%). An increase
in PR expression was seen in 22% of cases (median 22.5%,
range 2% to 100%), a decline in 43% of cases (median 40%,
range 5% to 100%), and, in 34% of cases, the percentage of
PR staining remained the same (Fig. 3).
HER2 Staining
Table 4 shows the HER2 status of the primary tumors
and metastases. One of the 77 patients had an HER2-positive
primary tumor and HER2-negative bone metastasis
(P=0.500; ODR 1.3%, 95% CI, 1%-7%). In this case, the
primary tumor had an IHC score of 3+ (therefore, no ISH was
performed), and the bone metastasis was IHC 2+ with no ISH
amplification.
Paired testing of the IHC score of the primary tumors
and the metastasis (n=77) showed no difference. In 25% of
cases, the metastasis had a higher IHC score than the primary
TABLE 2. Concordance and Discordance of ER Status of






Primary ER− 9 (11.7) 1 (1.3) 10 (13)
Primary ER+ 5 (6.5) 62 (80.5) 67 (87)
Total 14 (18.2) 63 (81.8) 77 (100)






FIGURE 2. Waterfall plot of the change in ER expression be-
tween the primary tumor and metastasis in 76 paired cases
(1 was excluded because no exact ER percentages could be
given). The horizontal dotted lines are drawn at −20% and
20%. The cases with receptor conversion showed an expression
difference of at least 60%. NN indicates ER-negative primary
tumor and ER-negative metastasis; NP, ER-negative primary
tumor and ER-positive metastasis; PN, ER-positive primary tumor
and ER-negative metastasis; PP, ER-positive primary tumor and
ER-positive metastasis.
TABLE 3. Concordance and Discordance of PR Status of






Primary PR− 13 (16.9) 4 (5.2) 17 (22.1)
Primary PR+ 12 (15.6) 48 (62.3) 60 (77.9)
Total 25 (32.5) 52 (67.5) 77 (100)






FIGURE 3. Waterfall plot of the change in PR staining between
the primary tumor and metastasis in 76 paired cases (1 case
was excluded because no exact PR percentages could be given).
The horizontal dotted lines are drawn at −20% and 20%. The
cases with receptor conversion showed an expression difference
of 2% to 100%. NN indicates PR-negative primary tumor and
PR-negative metastasis; NP, PR-negative primary tumor and
PR-positive metastasis; PN, PR-positive primary tumor and PR-
negative metastasis; PP, PR-positive primary tumor and PR-positive
metastasis.
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tumor; in 18%, the score was lower; and, in 57%, the score
remained the same. ISH gave equivocal results (Fig. 4).
Clinical Relevance
In six of the 77 patients (7.9%), clinically relevant
discordance of both ER and PR was observed; in five cases,
hormonal receptor (HR) status changed from positive to
negative; and, in one, from negative to positive. One of 5
patients, in whom HR status converted from positive (ER
100%, PR 90%) on the primary tumor to HR negative on
the bone metastasis, also underwent a nonosseous biopsy 3
weeks after the bone biopsy; this was ER negative and PR
positive (60%). One of 77 patients (1.3%) had HER2-
positive primary breast tumor, while the bone metastasis
was HER2 negative. This patient is one of the 5 cases in
which HR was discordant, with the primary tumor being
HR negative and the metastasis being HR positive. Alto-
gether, in 7.9% of MBC patients, the discordance affected
treatment choices. The disease-free survival (time between
the primary tumor and the metastasis) was not related to the
presence or absence of clinically relevant discordance, with
P= 0.82 for the entire group, versus patients with a change
of ER status and P= 0.93 for the entire group, versus pa-
tients’ with a change of PR status (Fig. 5).
DISCUSSION
This exploratory analysis shows that decalcification
with EDTA has very little effect on ER, PR, and HER2
results of breast cancer metastases in bone, measured by
IHC or ISH. After EDTA decalcification of bone meta-
stases, the clinically relevant discordance rate of these re-
ceptors at first presentation of MBC is low.
To our knowledge, this is the first study investigating
the most optimal decalcification method and its impact on
IHC and ISH results, by translating a methodological
experiment to a large prospective data set. These findings
support the regular use of bone biopsies in clinical practice
to assess receptor status, if the most optimal decal-
cification method is used. This is clearly of relevance in
bone-only disease, which is common in MBC.
ASCO/CAP recognizes that preanalytic variables
must be controlled to ensure that assay results reflect tu-
mor ER, PR, and HER2 status. In this setting, much at-
tention is focused in the ASCO/CAP guideline on optimal
fixation methods. Although the guideline states that
samples with decalcification artifacts should be rejected,
and that samples that were decalcified using a strong acid
may be rejected and testing should be repeated on a sep-
arate sample, no specific recommendations for optimal
bone decalcification have been made.12,13
With the optimal decalcification method with EDTA,
we showed, in our newly diagnosed MBC patients, that
discordance between primary breast cancer and bone
metastases was found for ER, PR, and HER2 status in
7.9%, 20.8%, and 1.3% of cases, respectively. The ER, PR,
and HER2 discordance rate in our population is less than
previously reported in other studies, namely 20.5%, 43.9%,
and 6.9%4 and 29.3%, 42.7%, and 8.5%, respectively.14 In
both studies, EDTA was used as the decalcification method.
Moreover, in recent studies with nonosseous metastases,
higher discordance rates were reported.14–16 Our lower dis-
cordance rate may be explained by the fact that our study
included only patients at first presentation of metastatic
disease. It is clear by now that breast cancer characteristics
may change also during the course of the metastatic disease
and following noncurative treatment. Clonal expansion,
particularly in case of a heterogenous primary tumor, might
explain discordance.17 Furthermore, we only included pa-
tients without rapid progression, selecting the more indolent
tumor type. In addition, true conversion might be in play, or
possibly a second primary tumor with distinct characteristics
as the source of the metastases. In any case, and despite the
low frequency of receptor discordance observed in our
study, it can have clear clinical implications. This underlines
the necessity to evaluate receptor status during the course of
the disease.
In our prospective cohort, only 14.3% of the women
had an HER2-positive primary tumor. Previously, HR
and HER2 of bone metastases were compared with the
primary breast cancer in a retrospective cohort. In that
study, merely 7.3% of 107 patients had an HER2-positive
primary breast cancer.18 As these data concern relatively
small subsets of patients, it would be of interest if results
could be confirmed in a larger cohort with HER2-positive
TABLE 4. Concordance and Discordance of HER2 Status of








66 (85.7) 0 66 (85.7)
Primary
HER2+
2 (2.6) 9 (11.7) 11 (14.3)
Total 68 (88.3) 9 (11.7) 77 (100)
FIGURE 4. Visualization of the cases in which a change of
human epidermal growth factor-2 immunohistochemistry
(HER2 IHC) score was observed (33/77). The 33 cases are de-
picted on the x-axis and the HER2 score can be appreciated
from the y-axis. For every case, the HER2 score for both the
primary tumor (blue dot) and metastasis (red box) is visualized.
In 25 cases, the score was 0 on the primary tumor and 1 on the
metastasis or vice versa. In the 8 remaining cases, the score was
3+ on the primary tumor and 2+ on the bone metastases
(n=2); a decline was seen from 2+ to either 1+ (n=2) or to 0
(n=1), and, in 3 cases, HER2 score went up from 0 to 2+.
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disease. In only 1 patient with clinical relevant discordance
of receptor status between the primary breast tumor and
bone metastasis, another nonosseous biopsy of a meta-
stasis was available. This additional biopsy confirmed the
loss of ER; however, contrary to the bone metastasis, it did
express PR, which can be explained by either heterogeneity
or false-negative results of the bone biopsy. For the other 6
patients with clinically relevant conversion, no other biopsy
was available to either confirm or reject these findings.
Although the results of our study show that HER2
status can reliably be determined after decalcification,
separating biopsies into softer and harder fragments to
avoid possible artifact by decalcification of tumor material
may also be considered.
In conclusion, in this exploratory analysis, we
showed that decalcification with EDTA does not interfere
with ER, PR, and HER2 expression in breast cancer bone
metastases. The incidence of clinically relevant dis-
cordance is low at first presentation of MBC. Our findings
support that bone metastases biopsies can reliably be used
to assess receptor status in clinical practice.
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Relapse time






FIGURE 5. Dot plot of the time between the diagnosis of the primary breast tumor and the bone biopsy of the metastasis (relapse
time) in months. The brown dots represent all patients in this study with median and interquartile range. Subgroups of patients
with change of ER status (patients in red dots), change of PR status (green dots), and change of HER2 status (blue dot); the median
relapse time of patients with ER or PR change is equal to the entire group with overlapping interquartile ranges.
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